Recent Articles in IPO/Stock Watch

Gland Pharma, an Indian generic drug maker majority owned by Shanghai Fosun Pharma, has filed to raise at least $650 million in an IPO on the Bombay and India National Stock Exchanges. In 2017, Fosun acquired a 74% stake in Gland for $1.1 billion. Gland makes complex generic injectible drugs that are sold largely in the US and EU. For India, Gland will be the first China controlled company listed on their domestic markets. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:

Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. Founded in 2017, Ocumension was incubated by 6 Dimensions Capital and now has built a portfolio of 16 ophthalmology drugs for China development, mainly through in-licensings. The portfolio includes three assets at or near clinical stage, and five candidates in preclinical development The company has raised $200 million in venture capital, including a $180 million B round one year ago. More details....

Stock Symbol: (HK 1477)

Share this with colleagues:

Hygeia Healthcare Holdings, China's largest provider of radiotherapy services for oncology, staged a $282 million IPO on the Hong Kong Exchange. Founded in 2009, Shanghai's Hygeia provides radiotherapy services to 50 hospitals owned by 15 hospital partners in nine provinces. It also manufacturers a radiotherapy system known as GyroKnife, a therapy used in cancer treatment, and it operates its own network of 10 oncology hospitals in China, providing over 2,000 beds. Hygeia closed its first trading session at HK$26.00 per share, a gain of 40.5% over the IPO price. More details....

Stock Symbol: (HK 6078)

Share this with colleagues:

Gan & Lee Pharma completed a Shanghai IPO that raised $360 million for the company, which specializes in insulin treatments. In initial trading, the stock was halted after it moved up to the Shanghai Exchange's 44% daily limit, a market capitalization of over $5 billion. The Beijing company's products consist of recombinant insulin analogues (third-generation insulin) and APIs that it markets in China and in foreign countries. The company's founder, Dr. Zhongru Gan, said Gan & Lee plans to develop R&D for oncology drugs, eukaryotic and prokaryotic protein engineering, and products for cardiovascular and metabolic diseases. More details....

Stock Symbol: (SHA: 603087)

Share this with colleagues:

Beijing's SinocellTech completed a $181 million IPO on Shanghai's STAR Board and nearly tripled in price during its initial trading session. The offering was priced at 25.64 RMB per share and ended its first session at 73.07 RMB, giving SinocellTech a market capitalization of nearly $4.5 billion. Sinocelltech is a biotech company that discovers and develops mAbs, recombinant proteins and vaccine products. The company has 23 products in its pipeline, including 21 novel differentiated drugs and two biosimilars. More details....

Stock Symbol: (SHA: 688520)

Share this with colleagues: